

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

# **APPENDIX 5**

#### FORMS RELATING TO LISTING

#### **FORM F**

**GEM** 

# **COMPANY INFORMATION SHEET**

Case Numbe	er:

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name: Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限公司

Stock code (ordinary shares): 8622

This information sheet contains certain particulars concerning the above company (the "Company") which is listed on GEM of The Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the GEM website on the internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 18 August 2023

### A. General

Place of incorporation: Cayman Islands

Date of initial listing on GEM: 13 December 2018

Name of Sponsor(s): RHB Capital Hong Kong Limited

Names of directors:

(please distinguish the status of the directors - Executive, Non-Executive or Independent

Non-Executive)

**Executive Directors** 

Zhang Shuguang (張曙光)

Zhang Chunguang (張春光)

Poon Lai Yin Michael (潘禮賢)

He Jiaming (何嘉明)

Independent non-executive Directors

Chow Kwok Fai Joseph (周國輝)

Cheng Faat Ting Gary (鄭發丁)

Chan Kin Sang (陳健生)

Chow Ching Man (周靖文)

Page 1 of 5 Oct 2020

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Name(s) of substantial shareholder(s): (as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company

Name of Shareholder	Number of Shares	Percentage of Shareholding
Crystal Grant Limited ("Crystal Grant") (Notes 1 and 3)	242,056,000	57.8%
Ever Charming Inc. ("Ever Charming") (Notes 2 and 3)	242,056,000	57.8%
Zhang Shuguang ("Mr. Zhang") (Notes 1 and 3)	242,056,000	57.8%
Chang Yim Yang ("Mr. Chang") (Notes 2 and 3)	242,056,000	57.8%

# Notes:

- Crystal Grant is beneficially owned as to 100% by Mr. Zhang. Mr. Zhang is deemed to be interested in all the Shares held by Crystal Grant for the purpose of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO").
- Ever Charming is beneficially owned as to 100% by Mr. Chang. Mr. Chang is deemed to be interested in all the Shares held by Ever Charming for the purpose of the SFO.
- 3. Pursuant to the Acting-in-concert Confirmation dated 16 November 2017, Mr. Zhang and Mr. Chang have confirmed, among others that they are parties acting in concert since September 2003, and will, until entering into a letter of termination maintain the acting in concert relationship with respect to each member of our Group. As such, Mr. Zhang and Mr. Chang are collectively deemed to be interested in all the Shares and other securities of the Company held by each other under the SFO. The aggregate interest in 242,056,000 Shares, which include 238,056,000 Shares and 4,000,000 share options, are deemed to be interested by them in aggregate under the SFO, consist of (i) 144,032,000 Shares held by Crystal Grant, a company wholly owned by Mr. Zhang, in which Mr. Zhang is deemed to be interested under the SFO; (ii) 94,024,000 Shares held by Ever Charming, a company wholly owned by Mr. Chang, in which Mr. Chang is deemed to be interest under the SFO; and (iii) 4,000,000 share options granted to Mr. Zhang on 9 April 2020.

Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company:

N/A

Financial year end date:

31 December

Registered address:

Cricket Square, Hutchins Drive, P.O. Box 2681,

Grand Cayman KY1-1111, Cayman Islands

Page 2 of 5 Oct 2020

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Head office and principal place of business: Head office and principal place of business in Hong Kong

3rd Floor, Effectual Building, 16 Hennessy Road,

Wanchai, Hong Kong

Principal place of business in the PRC 1-3/F, Building D, Shenzhen Junxuan,

No.16 Yinkui Road, Kui Xin Community, Kui Chong Office, Dapeng New District,

Shenzhen, the PRC

Web-site address (if applicable): www.huakangbiomedical.com

Share registrar: Principal share registrar and transfer office in Cayman Islands

Conyers Trust Company (Cayman) Limited

Cricket Square, Hutchins Drive, P.O. Box 2681,

Grand Cayman KY1-1111,

Cayman Islands

Hong Kong branch share registrar and transfer office

Tricor Investor Services Limited 17/F., Far East Finance Centre,

16 Harcourt Road, Hong Kong

Auditors: Mazars CPA Limited

42/F., Central Plaza,

18 Harbour Road, Wanchai,

Hong Kong

# **B. Business activities**

A medical device group specialised in the research and development, manufacture and sale of a wide range of invitro diagnostic ("IVD") reagents and auxiliary reproductive supplies and equipment in the People's Republic of China ("PRC").

# C. Ordinary shares

Number of ordinary shares in issue: 418,472,000

Par value of ordinary shares in issue: HK\$0.01 per Share

Board lot size (in number of shares): 8,000

Name of other stock exchange(s) on N/A which ordinary shares are also listed:

D. Warrants

Stock code: N/A

Board lot size: N/A

Expiry date: N/A

Exercise price: N/A

Page 3 of 5 Oct 2020

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Conversion ratio: N/A
(Not applicable if the warrant is denominated in dollar value of conversion right)

No. of warrants outstanding: N/A

No. of shares falling to be issued upon N/A the exercise of outstanding warrants:

# E. Other securities

Details of any other securities in issue.

(i.e. other than the ordinary shares described in C above and warrants described in D above but including options granted to executives and/or employees).

On 9 April 2020, the Company announced the granting of an aggregate of 26,008,000 share options, in which 16,000,000 Share Options were granted to the executive Directors of the Company, at an exercise price of HK\$0.125 per share of the Company to the eligible persons under the Share Option Scheme. The market price of the Company's shares at the date of grant was HK\$0.125 per share. All of the share options are exercisable from the date of acceptance by a grantee to 8 April 2030 (both days inclusive). Each of the grantees had paid HK\$1 to the Company on acceptance of the offer of share option. No share options have been lapsed, however, 4,000,000 and 2,504,000 share options have been exercised and forfeited, respectively, up to date of this letter.

(Please include details of stock code if listed on GEM or the Main Board or the name of any other stock exchange(s) on which such securities are listed).

If there are any debt securities in issue that are guaranteed, please indicate name of guarantor.

N/A

Page 4 of 5 Oct 2020

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

# Responsibility statement

The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet ("the Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading or deceptive and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Submitted by: Chau Lai Ki

(Name)

Title: Company Secretary

(Director, secretary or other duly authorised officer)

# NOTE

Pursuant to rule 17.52 of the GEM Listing Rules, the Company must submit to the Exchange (in the electronic format specified by the Exchange from time to time) for publication on the GEM website a revised information sheet as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

Page 5 of 5 Oct 2020